中文 | English
Return
Total: 9 , 1/1
Show Home Prev Next End page: GO
Author:(Yuanfeng SHI)

1.Inreasing Efficacy and Decreasing foxicity of Chinese Medicine Combined with Oxaliplatin in the Treatment of Cancer

Yuanfeng ZHANG ; Tuo SHI ; Ming XIE ; Chenglong LI

China Pharmacist 2017;20(7):1218-1223

2.Induction and in vitro culture of hairy roots of Dianthus caryophyllus and its plant regeneration.

Heping SHI ; Yuanfeng ZHU ; Bei WANG ; Jiangbing SUN ; Shengqin HUANG

Chinese Journal of Biotechnology 2014;30(11):1742-1750

3.Evaluation of kinetics of PML-RAR_? fusion gene in children with acute promyelocytic leukemia

Yaping YU ; Jihong YANG ; Yuanfeng FU ; Haining LIU ; Yongping ZHAI ; Ping SHI ; Yume TANG

Journal of Medical Postgraduates 2004;0(02):-

4.Optimal pressure for facemask ventilation during induction of general anesthesia in adult patients:real-time ultrasonographic measurement of antral cross-sectional area

Lihua HANG ; Shiyou WEI ; Zhenkai XU ; Weiwei SHU ; Yuanfeng CHEN ; Zheng CHEN ; Leilei SHI ; Donghua SHAO

Chinese Journal of Anesthesiology 2017;37(4):461-463

5.CT diagnosis and classification of simple renal adipose capsule herniation

Wujiang YU ; Weihan HUANG ; Bin LIU ; Yuanfeng SHI

Journal of Practical Radiology 2019;35(6):892-894,898

6.Progress in noninvasive assessment of fluid responsiveness

Jiguang LI ; Yuanfeng SHI ; Caihong GU ; Shiqi LU

Chinese Journal of General Practitioners 2019;18(1):85-88

7.Significance of peripheral perfusion index in early diagnosis and goal-directed therapy of septic shock patients: a prospective single-blind randomized controlled trial

Yuanfeng SHI ; Ruihong YIN ; Yanli WANG ; Jiguang LI ; Xiaobing CHEN ; Yongpeng XIE ; Caihong GU ; Xiuzhen ZOU ; Kexi LIU

Chinese Critical Care Medicine 2017;29(12):1065-1070

8.Factors influencing induction and in vitro culture of hairy roots in Phytolacca americana L.

Heping SHI ; Yuanfeng ZHU ; Po Keung Eric TSANG ; Cheuk Fai Stephen CHOW ; Zhen'ao YU ; Shengqin HUANG

Chinese Journal of Biotechnology 2017;33(2):272-283

9.Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations.

Chen SHI ; Cong ZHANG ; Zhiwen FU ; Jinmei LIU ; Yuanfeng ZHOU ; Bao CHENG ; Cong WANG ; Shijun LI ; Yu ZHANG

Acta Pharmaceutica Sinica B 2023;13(6):2613-2627

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 9 , 1/1 Show Home Prev Next End page: GO